Podstawa prawna: art. 56. 1. 2 of Act on Public Offering.
„Sopharma” AD (the Company) notifies that in compliance with the decision of the Board of Directors of „Sopharma” AD dated 26.10.2022, the Company submitted for approval to the Financial Supervision Commission an Agreement for conversion by merger of the subsidiary company „Biopharm-engineering” AD, UIC: 119055339 in „Sopharma” AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on Public Offering of Securities.
Więcej na: http://biznes.pap.pl/pl/reports/espi/all,0,0,0,1
kom espi zdz
Wiadomości dystrybuowane przez: pap-mediaroom.pl
